Search

Your search keyword '"Dudczak, Robert"' showing total 15 results
Start Over Author "Dudczak, Robert" Publisher wiley
15 results on '"Dudczak, Robert"'

2. Pharmacoresistance in Epilepsy: A Pilot PET Study with the P-Glycoprotein Substrate R -[11 C]verapamil

Author

Langer, Oliver, primary, Bauer, Martin, additional, Hammers, Alexander, additional, Karch, Rudolf, additional, Pataraia, Ekaterina, additional, Koepp, Matthias J., additional, Abrahim, Aiman, additional, Luurtsema, Gert, additional, Brunner, Martin, additional, Sunder-Plassmann, Raute, additional, Zimprich, Friedrich, additional, Joukhadar, Christian, additional, Gentzsch, Stephan, additional, Dudczak, Robert, additional, Kletter, Kurt, additional, Müller, Markus, additional, and Baumgartner, Christoph, additional

Published
2007
Full Text
View/download PDF

10. Characterization of123I-vascular endothelial growth factor-binding sites expressed on human tumour cells: Possible implication for tumour scintigraphy

Author

Li, Shuren, primary, Peck-Radosavljevic, Markus, additional, Koller, Elisabeth, additional, Koller, Franz, additional, Kaserer, Klaus, additional, Kreil, Anna, additional, Kapiotis, S., additional, Hamwi, A., additional, Weich, Herbert A., additional, Valent, Peter, additional, Angelberger, Peter, additional, Dudczak, Robert, additional, and Virgolini, Irene, additional

Published
2001
Full Text
View/download PDF

14. A positron emission tomography microdosing study with a potential antiamyloid drug in healthy volunteers and patients with Alzheimer's disease.

Author

Bauer M, Langer O, Dal-Bianco P, Karch R, Brunner M, Abrahim A, Lanzenberger R, Hofmann A, Joukhadar C, Carminati P, Ghirardi O, Piovesan P, Forloni G, Corrado ME, Lods N, Dudczak R, Auff E, Kletter K, and Müller M

Subjects
Adult, Aged, Alzheimer Disease metabolism, Amyloid metabolism, Area Under Curve, Biological Availability, Blood-Brain Barrier metabolism, Carbon Radioisotopes, Chromatography, High Pressure Liquid, Dose-Response Relationship, Drug, Female, Humans, Injections, Intravenous, Male, Molecular Structure, Naphthols blood, Naphthols therapeutic use, Neuroprotective Agents blood, Neuroprotective Agents pharmacokinetics, Neuroprotective Agents therapeutic use, Pilot Projects, Time Factors, Tissue Distribution, Alzheimer Disease drug therapy, Amyloid antagonists & inhibitors, Naphthols pharmacokinetics, Positron-Emission Tomography methods
Abstract

This work describes a microdosing study with an investigational, carbon 11-labeled antiamyloid drug, 1,1'-methylene-di-(2-naphthol) (ST1859), and positron emission tomography (PET) in healthy volunteers (n = 3) and patients with Alzheimer's disease (n = 6). The study aimed to assess the distribution and local tissue pharmacokinetics of the study drug in its target organ, the human brain. Before PET studies were performed in humans, the toxicologic characteristics of ST1859 were investigated by an extended single-dose toxicity study according to guidelines of the Food and Drug Administration and European Medicines Agency, which are relevant for clinical trials with a single microdose. After intravenous bolus injection of 341 +/- 21 MBq [(11)C]ST1859 (containing <11.4 nmol of unlabeled ST1859), peripheral metabolism was rapid, with less than 20% of total plasma radioactivity being in the form of unchanged parent drug at 10 minutes after administration. In both the control and patient groups, uptake of radioactivity into the brain was relatively fast (time to reach maximum concentration, 9-17 minutes) and pronounced (maximum concentration [standardized uptake value], 1.3-2.2). In both healthy volunteers and patients, there was a rather uniform distribution of radioactivity in the brain, including both amyloid-beta-rich and -poor regions, with slow washout of radioactivity (half-life, 82-185 minutes). In conclusion, these data provide important information on the blood-brain barrier penetration and metabolism of an investigational antiamyloid drug and suggest that the PET microdosing approach is a useful method to describe the target-organ pharmacokinetics of radiolabeled drugs in humans.

Published
2006
Full Text
View/download PDF

15. Influence of functional haplotypes in the drug transporter gene ABCB1 on central nervous system drug distribution in humans.

Author

Brunner M, Langer O, Sunder-Plassmann R, Dobrozemsky G, Müller U, Wadsak W, Krcal A, Karch R, Mannhalter C, Dudczak R, Kletter K, Steiner I, Baumgartner C, and Müller M

Subjects
Adult, Area Under Curve, Carbon Radioisotopes administration & dosage, Carbon Radioisotopes pharmacokinetics, Case-Control Studies, Central Nervous System Agents administration & dosage, Double-Blind Method, Haplotypes, Humans, Injections, Intravenous, Male, Positron-Emission Tomography, Tissue Distribution, Verapamil administration & dosage, Central Nervous System metabolism, Central Nervous System Agents pharmacokinetics, Genes, MDR, Verapamil pharmacokinetics
Abstract

Background and Objective: Single nucleotide polymorphisms in the human multidrug-resistance gene ABCB1 have been reported to be associated with altered expression and function of P-glycoprotein, an efflux transporter, expressed at the blood-brain barrier. To test whether certain ABCB1 haplotypes contribute to interindividual differences in central nervous system drug distribution, brain distribution of a model P-glycoprotein substrate, the calcium channel inhibitor verapamil, was measured by positron emission tomography (PET) in 2 groups of healthy volunteers., Methods: Ten homozygous carriers (cases) of the TTT haplotype (3435T, 1236T, and 2677T) and 10 controls homozygous for the wild-type CGC haplotype (3435C, 2677G, and 1236C) were administered a mean intravenous bolus of 412 +/- 114 MBq carbon 11-labeled verapamil containing less than 15 nmol of unlabeled verapamil. PET imaging of brain tissue and venous blood sampling were performed for 1 hour after dosing., Results: As a measure of brain penetration, the ratio of PET area under the time-radioactivity curve (AUC) to plasma AUC was calculated from time-radioactivity curves, with a mean ratio of 1.1 +/- 0.3 (SD) (95% confidence interval, 0.9-1.3) for cases and 1.1 +/- 0.2 (95% confidence interval, 0.9-1.2) for controls, respectively (P = .96). Mean brain AUC values were 31.2 +/- 3.9 and 35.7 +/- 5.7 for the TTT and CGC haplotype, respectively (P = .11). Plasma AUCs were not significantly different., Conclusion: No difference in the brain distribution of [(11)C]verapamil could be detected in healthy volunteers differing in ABCB1 haplotypes.

Published
2005
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results